Loading...
StocksRunner logo
 
 
Arrowhead Pharmaceut
36.55
+1.19%
 
ARWR Arrowhead Pharmaceuticals
Last Price
Change
36.55
 
+1.19%
 
 
 

 
Sentiment
 
  Login to display
 
 

34.96

25.23

34.99

34.46

 
 
1m
3m
6m
1y
 

Summary

  Login to display Arrowhead Pharmaceuticals (ARWR) recommendation from the last 90 days from financial news and social media.
 

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Rewards

 Trading below its fair value

 
 

Risk Level

 
StocksRunner
 

Arrowhead Pharmaceuticals (ARWR) has Moderate Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

4.56
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.40
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.60
 

StocksRunner

 Outperform the market

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
86%
89%
60%
100%
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have positive views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
86%
10%
Positive
Negative
18 out of 21
events present
2 out of 21
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
36.05
+3.98%
 
Buy Rating
2 Weeks Ago
35.61
-1.85%
 
Buy Rating
2 Month Ago
40.27
+13.81%
 
Upgrade
2 Month Ago
28.60
+9.02%
 
Top Headlines

piper sandler maintains arrowhead pharmaceuticals (arwr) overweight recommendation. fintel reports that on june 2 2023 piper sandler maintained coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a overweight recommendation. analyst price f

Fri Jun 2, 2023

Rating

chardan capital reiterates arrowhead pharmaceuticals (arwr) buy recommendation. fintel reports that on june 2 2023 chardan capital reiterated coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a buy recommendation. analyst price forecast s

Fri Jun 2, 2023

Rating

arwr makes notable cross below critical moving average. in trading on thursday shares of arrowhead pharmaceuticals inc (symbol: arwr) crossed below their 200 day moving average of $33.85 changing hands as low as $33.57 per share. arrowhead

Thu May 25, 2023

Momentum

chardan capital reiterates arrowhead pharmaceuticals (arwr) buy recommendation. fintel reports that on may 24 2023 chardan capital reiterated coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a buy recommendation. analyst price forecast s

Wed May 24, 2023

Rating

arrowhead pharmaceuticals remains a buy for pipeline potential.

Fri May 19, 2023

Rating

goldman sachs maintains arrowhead pharmaceuticals (arwr) buy recommendation. fintel reports that on may 3 2023 goldman sachs maintained coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a buy recommendation. analyst price forecast suggest

Wed May 3, 2023

Rating

rbc capital reiterates arrowhead pharmaceuticals (arwr) outperform recommendation. fintel reports that on may 3 2023 rbc capital reiterated coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a outperform recommendation. analyst price forec

Wed May 3, 2023

Potential

smbc nikko initiates coverage of arrowhead pharmaceuticals (arwr) with outperform recommendation. fintel reports that on april 26 2023 smbc nikko initiated coverage of arrowhead pharmaceuticals (nasdaq:arwr) with a outperform recommendation. ana

Thu Apr 27, 2023

Potential

arrowhead pharmaceuticals reveals data from healthy volunteers for its asthma hopeful stock soars. ) announced interim results from an ongoing phase 1/2 clinical study of aro-rage in

Tue Apr 25, 2023

Momentum

why shares of arrowhead pharmaceuticals are up tuesday. what happened shares of clinical-stage biotech company arrowhead pharmaceuticals (nasdaq: arwr) were up more than 17% tuesday morning after the company released interim results from a phas

Tue Apr 25, 2023

Momentum
Momentum

arrowhead pharma surges 16% on positive data from early-stage trial of inflammatory pulmonary diseases therapy.

Tue Apr 25, 2023

Activity
Momentum

svb securities upgrades arrowhead pharmaceuticals (arwr). fintel reports that on april 12 2023 svb securities upgraded their outlook for arrowhead pharmaceuticals (nasdaq:arwr) from market perf

Wed Apr 12, 2023

Rating

analyst upgrades arrowhead pharma citing attractive risk/reward. ) to outperform from market perform on attractive risk-reward following shares'. underperformance relative to larger cap oligo therapy peers. svb securities raised the

Wed Apr 12, 2023

Potential
Rating
Rating

arrowhead adds 11% as svb upgrades on compelling risk-reward setup.

Wed Apr 12, 2023

Potential
Rating

arrowhead: a compelling investment in rnai therapeutics with significant upside potential.

Tue Apr 11, 2023

Activity
Potential

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ARWR alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ARWR Arrowhead Pharmaceuticals

Last Price
36.55
Change
+1.19%
 

Summary

  Login to display Arrowhead Pharmaceuticals (ARWR) recommendation from the last 90 days from financial news and social media.

 
 
34.96
25.23
34.99
34.46
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

Rewards

 Outperform the market

Rewards

 Trading below its fair value

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
89%
60%
100%
On Track
On Track
On Track
 
86%
10%
Positive
Negative
18 out of 21
events present
2 out of 21
events present
 

Street Opinion

Street view is extremely ish and have positive views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

NA
 
 
 

Rating

×
 

Rating

4.56
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

3.40
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

4.60
 

StocksRunner

 Outperform the market

StocksRunner

 Trading below its fair value

 
 

Analysts Opinion

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Arrowhead Pharmaceuticals (ARWR) has Moderate Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
36.05
+3.98%
 
Buy Rating
2 Weeks Ago
35.61
-1.85%
 
Buy Rating
2 Month Ago
40.27
+13.81%
 
Upgrade
2 Month Ago
28.60
+9.02%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ARWR Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines